Consensus statement concerning cardiotoxicity occurring during haemotopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis

Bone Marrow Transplantation

Volumn 34, Issue 10, 2004, Pages 877-881

  Saccardi, R ^a,m   Tyndall, A ^b   Coghlan, G ^c   Denton, C ^c   Edan, G ^d   Emdin, M ^e   Farge, D ^f   Fassas, A ^g   Finke, J ^h   Furst, D ⁱ   Lassus, M ^j   Mancardi, G ^k   Miniati, I ^a   Mini, E ^a   Pagliai, F ^a   Passweg, J ^b   Pignone, A ^a   van Laar, J M ^l   Bocelli Tyndall, C ^b   Matucci Cerinic, M ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF BASEL   (Switzerland)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^f SAINT LOUIS HOSPITAL   (France)

^g George Papanicolaou Hospital   (France)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j Oncology Department   (Italy)

^k UNIVERSITY OF GENOA   (Italy)

^l LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^m Bone Marrow Transplantation Unit   (Italy)

more..

Author keywords

Autoimmune diseases; Cardiotoxicity; HSCT

Indexed keywords

CYCLOPHOSPHAMIDE; MITOXANTRONE;

AUTOIMMUNE DISEASE; CARDIOTOXICITY; CONFERENCE PAPER; DISEASE SEVERITY; DOPPLER ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART FUNCTION TEST; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOLTER MONITORING; HUMAN; MORTALITY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; SYSTEMIC SCLEROSIS;

ANTHRACYCLINES; AUTOIMMUNE DISEASES; CYCLOPHOSPHAMIDE; HEART DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE SCLEROSIS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; SCLERODERMA, SYSTEMIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 9444291907     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704656     Document Type: Conference Paper

References (32)

1. Van Laar JM, Tyndall A. Intense immunosuppression and stem-cell transplantation for patients with severe rheumatic autoimmune disease: a review. Cancer Control 2003; 10: 57-65.
2. Coghlan JG, Mukerjee D. The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology. Curr Opin Rheumatol 2001; 13: 495-499.
3. Di Bello V, Ferri C, Giorgi D et al. Ultrasonic videodensitometric analysis in scleroderma heart disease. Coronary Artery Dis 1999; 10: 103-110.
4. Edan G, Miller D, Clanet M et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62: 112-118.
5. Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002; 360: 2018-2025.
6. Binks M, Passweg JR, Furst D et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-584.
7. Farge D, Marolleau JP, Zohar S et al. Intensification et Autogreffe dans les Maladies Auto Immunes Resistantes (ISAMAIR) Study Group. Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study. Br J Haematol 2002; 119: 726-739.
8. Appelbaum F, Strauchen JA, Graw Jr RG et al. Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1976; 1: 58-62.
9. Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 1986; 68: 1114-1118.
10. Gottdiener JS, Appelbaum FR, Ferrans VJ et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-763.
11. Ayash LJ, Wright JE, Tretyakov O et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10: 995-1000.
12. Murdych T, Weisdorf DJ. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977 1997. Bone Marrow Transplant 2001; 28: 283-287.
13. Sladek NE. Metabolism and pharmacokinetics behavior of cyclophosphamide and related oxazaphosphorines. In: Powis G (ed.). Anticancer Drugs Reactive Metabolism and Drug Interactions. Pergamon Press: Tarrytown, NY, 1994; pp 79-156.
14. Chen TL, Passos-Coelho JL, Noe DA et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 1995; 55: 810-816.
15. Kjellman UW, Hallgren P, Bergh CH et al. Weaning from mechanical support in a patient with acute heart failure and multiple sclerosis. Ann Thorac Surg 2000; 69: 628-630.
16. Flachenecker P, Wolf A, Krauser M et al. Cardiovascular autonomic dysfunction in multiple sclerosis: correlation with orthostatic intolerance. J Neurol 1999; 246: 578-586.
17. Benjamin RS. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin Oncol 1995; 22: 11-13.
18. Steinherz LJ, Steinherz PG, Tan CT et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-1677.
19. Goorin AM, Chauvenet AR, Perez-Atayde AR et al. Initial congestive heart failure, six to ten years after doxorubicin chemotherapy for childhood cancer. J Pediatr 1990; 116: 144-147.
20. Lipshultz SE, Colan SD, Gelber RD et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-815.
21. McSweeney PA, Nash RA, Sullivan KM et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood 2002; 100: 1602-1610.
22. Rosen O, Massenkeil G, Hiepe F et al. Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): no evidence for cyclophosphamide-induced cardiomyopathy. Bone Marrow Transplant 2001; 27: 657-658.
23. Cowie MR. NICE guidelines on heart failure. Clin Med 2003; 3: 399-401.
24. Snowden JA, Hill GR, Hunt P et al. Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide. Bone Marrow Transplant 2000; 26: 309-313.
25. Okumura H, Iuchi K, Yoshida T et al. Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 2000; 104: 158-163.
26. Morandi P, Ruffini PA, Benvenuto GM et al. Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7g/m(2)) cyclophosphamide. Bone Marrow Transplant 2001; 28: 277-282.
27. Auner HW, Tinchon C, Linkesch W et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003; 82: 218-222. Epub 2003, March 25.
28. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer 2002; 86: 1697-1700.
29. Mori T, Yanagi N, Maruyama T et al. Left ventricular diastolic dysfunction induced by cyclophosphamide in blood stem cell transplantation. Jpn Heart J 2002; 43: 249-261.
30. Tjeerdsma G, Meinardi MT, van Der Graaf WT et al. Early detection of anthracycline induced cardiotoxicity in asymptomatic patients with normal left ventricular systolic function: autonomic versus echocardiographic variables. Heart 1999; 81: 419-423.
31. Denton CP, Black CM. Pulmonary hypertension in systemic sclerosis. Rheum Dis Clin North Am 2003; 29: 335-349.
32. Farge D, Passweg JR, van Laar JM et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: an extended report from the EULAR/EBMT registry. Ann Rheumatic Dis 2004; 63 974-981.